Showing 20,721 - 20,740 results of 34,844 for search '(( 50 ((a decrease) OR (nn decrease)) ) OR ( e ((point decrease) OR (fold decrease)) ))', query time: 0.93s Refine Results
  1. 20721
  2. 20722
  3. 20723
  4. 20724
  5. 20725
  6. 20726

    Longitudinal study on changes in COVID-19 vaccination intentions in Benin and Senegal: Insights from Generalized Estimating Equations (GEE) by Ibrahima Gaye (8462562)

    Published 2025
    “…Vaccination intent increased more significantly in Senegal (+12.5 points, <i>p</i> = .000) than in Benin (+5.0 points, <i>p</i> = .089). There was a statistically significant increase in vaccine intent among women (+19.9 points) and individuals under 25 (+15.6 points) in Senegal, whereas in Benin, younger respondents showed a decrease (−11.5 points). …”
  7. 20727
  8. 20728
  9. 20729
  10. 20730
  11. 20731

    Pituitary Adenylate Cyclase Activating Peptide (1-38) and its analog (Acetyl-[Ala15, Ala20] PACAP 38-polyamide) reverse methacholine airway hyperresponsiveness in rats by Mounira Tlili (12847046)

    Published 2022
    “…PACAP38 analog prevents effectively bronchial smooth muscle layer thickness, mucus hypersecretion and lumen decrease. Therefore, it may constitute a potent therapeutic bronchodilator.…”
  12. 20732
  13. 20733
  14. 20734

    Effect of mini-dose ready-to-use liquid glucagon on preventing exercise-associated hypoglycemia in adults with type 1 diabetes by Ronnie Aronson (3705877)

    Published 2023
    “…</p> <p>Research Design and Methods</p> <p>Individuals initially participated in the in-clinic training phase for which they were randomized to a crossover design: 150 µg glucagon (treatment arm A) or placebo (arm B) subcutaneously, immediately before exercise, plus 50% reduction in continuous subcutaneous insulin infusion (CSII) basal delivery rate. …”
  15. 20735

    Effects of PD-0332991 on BSG cell lines derived from genetically engineered mouse models. by Kelly L. Barton (465812)

    Published 2013
    “…<p>Cells were treated with PD-0332991 for 48 hours before being harvested for MTT or BrdU assays to assess cell survival and proliferation, respectively. (A) MTT assays (left panel) show minimal cytotoxic activity at doses up to 5µM in cell lines derived from PDGF-B; Ink4a-ARF deficient BSGs. …”
  16. 20736
  17. 20737
  18. 20738
  19. 20739
  20. 20740